Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Study of the Effects of Eculizumab in CD59 Deficiency

Next Previous
X
Search
Trial Profile

An Open Label Study of the Effects of Eculizumab in CD59 Deficiency

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Haemolysis
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 06 Dec 2016 Results of this and one other study presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 18 Oct 2016 New trial record
    • 29 Aug 2016 According to the results published in the Annals of Neurology, the study was initially designed to include 8 months of eculizumab treatment. After 8 months the study seemed to be life saving and hence was extended to 2 years
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top